Halozyme Therapeutics Inc (HALO)

[maumar]

Data from Halo 202 are a little confusing and not quite as good as many of us hoped and some of us expected. My sense is the market is giving Halo 301 a 60% chance of success.

It's hard to tell from the revenue guidance for 2017 what kind of enhanze royalties Halo expects. Perhaps a 20% increase from 2016?

The good news is Mabthera SC is almost guaranteed to be approved in June. I think there is strong possibility that royalties will double in 2018.

Royalties may double again in 2019 if Roche files for Herceptin SC in US in the second half of 2017 or early 2018.

"The U.S. patent on Herceptin is slated to lapse in 2019, although some industry analysts believe a biosimilar could be launched as soon as 2018."

http://www.foxnews.com/health/2016/11/30/pfizers-herceptin-biosimilar-succeeds-in-key-breast-cancer-study.html